Anticoagulant-associated calciphylaxis: analysis of USFDA adverse event report system and clinical feature analysis of reported cases

This evaluation characterized calciphylaxis safety signals from pharmacovigilance data and literature review. Warfarin emerged as the most strongly associat.ed based on both sources. While limitations preclude causality determination, findings warrant attention regarding warfarin's calciphylaxis risk profile, especially in higher-risk populations. Additional research is needed, including controlled trials, to validate this relationship and optimize management.